Drug Information

Drug (ID: DG00890) and It's Reported Resistant Information

• Name: Stanozolol
• Synonyms: Stanozolol; Winstrol; Androstanazole; Androstanazol; 10418-03-8; Stromba; Stanazolol; Tevabolin; Winstrol Depot; Strombaject; Estazol; Winstroid; Winstrol V; Estanozolol; Stanozololum; WIN 14833; Anabol; UNII-4R1VB9P8V3; Androstanazolestanazol; NSC 233046; 4R1VB9P8V3; CHEBI:9249; 17-Methyl-2'H-5alpha-androst-2-eno(3,2-c)pyrazol-17beta-ol; NSC-43193; WIN-14833; (1S,3aS,3bR,5aS,10aS,10bS,12aS)-1,10a,12a-trimethyl-1,2,3,3a,3b,4,5,5a,6,8,10,10a,10b,11,12,12a-hexadecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-ol; Stanozolo [DCIT]; Androstanazole (VAN); Stanozolo; Stanozolol (1'H form); Winstrol-V; Stanozololum [INN-Latin]; Estanozolol [INN-Spanish]; (1S,2S,10S,13R,14S,17S,18S)-2,17,18-trimethyl-6,7-diazapentacyclo[11.7.0.0^{2,10}.0^{4,8}.0^{14,18}]icosa-4(8),5-dien-17-ol; Cyclopenta(7,8)phenanthro(2,3-c)pyrazol-1-ol, 1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydro-1,10a,12a-trimethyl-; HSDB 3185; SR-05000001522; Stanozolol (2'H form); 17 -Methyl-5 -androstano[3,2-c]pyrazol-17 -ol; EINECS 233-894-8; NSC 43193; Stanozolol ciii; NSC-233046; Winstrol (TN); 2'H-Androst-2-eno(3,2-c)pyrazol-17-ol, 17-methyl-, (5alpha,17beta)-; Winstrol; ; ; Stanabol; 17-Methyl-5alpha-androstano(3,2-c)pyrazol-17beta-ol; 302-96-5; Stanozolol [USAN:USP:INN:BAN:JAN]; 17-beta-Hydroxy-17-alpha-methylandrostano(3,2-c)pyrazole; 17beta-Hydroxy-17alpha-methyl-androstano(3,2-c)pyrazole; 17-Methyl-pyrazolo(4',3':2,3)-5alpha-androstan-17beta-ol; 17-Methylpyrazolo(4',3':2,3)-5alpha-androstan-17beta-ol; 17beta-Hydroxy-17-methyl-5alpha-androstano(3,2-c)pyrazole; 17alpha-Methyl-17beta-hydroxy-5alpha-androstano(3,2-c)pyrazole; 2'H-5alpha-Androst-2-eno(3,2-c)pyrazol-17beta-ol, 17-methyl-; 2,3-(4',3'-Pyrazolo)-5alpha-androstan-17beta-ol, 17-methyl-; DSSTox_CID_24128; DSSTox_RID_97564; stanozolol--dea schedule iii; DSSTox_GSID_44128; SCHEMBL44099; SCHEMBL44100; Stanozolol (JAN/USP/INN); 1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-Hexadecahydro-1,10a,12a-trimethylcyclopenta(7,8)-phenanthro(2,3-c)pyrazol-1-ol; MLS001424321; Stanozolol, analytical standard; CHEMBL2079587; DTXSID3044128; GTPL10369; HMS2052H11; HMS2090P03; HMS3713K06; BCP12548; HY-B0899; NSC43193; WIN14833; ZINC4097376; Tox21_113993; 1'H-Androstano(3,2-c)pyrazol-17-ol, 17-methyl-, (5-alpha,17-beta)-; AKOS005067278; Stanozolol 1.0 mg/ml in Acetonitrile; AM84316; CCG-101186; CCG-220452; CS-4363; DB06718; MCULE-6473940948; NC00436; NCGC00344550-01; (1S,3aS,3bR,5aS,10aS,10bS,12aS)-1,10a,12a-trimethyl-1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-ol; AC-16140; AC-33164; AS-35198; CPD000058878; Cyclopenta(7,8)phenanthro(2,3-c)pyrazol-1-ol, 1,2,3,3a,3b,4,5,5a,6,8,10,10a,10b,11,12,12a-hexadecahydro-1,10a,12a-trimethyl-; SMR000058878; CAS-10418-03-8; C07311; D00444; 17-Methyl-5a-androstano[3,2-c]pyrazol-17b-ol; AB00443942-03; AB00443942-05; 418S038; SR-05000001522-1; SR-05000001522-2; W-108823; 17a-Methyl-17b-hydroxy-5a-androstano(3,2-c)pyrazole; 17b-Hydroxy-17-methyl-5a-androstano[3,2-c]pyrazole; 17b-Hydroxy-17a-methyl-5a-androstano[3,2-c]pyrazole; Q63409446; 17-Methyl-pyrazolo[4',3':2,3]-5a-androstan-17b-ol; Z1541662177; 17-Methyl-1'H-5alpha-androstano[3,2-c]pyrazol-17beta-ol; Stanozolol, European Pharmacopoeia (EP) Reference Standard; (5a,17b)-17-methyl-2'H-Androst-2-eno[3,2-c]pyrazol-17-ol; 2,3'-Pyrazolo)-5.alpha.-androstan-17.beta.-ol, 17-methyl-; 5alpha-Androstane-17alpha-methyl-17beta-ol-[3,2-c]pyrazole; 2'H-5a-Androst-2-eno[3,2-c]pyrazol-17b-ol, 17-methyl- (8CI); 17alpha-Methyl-17beta-hydroxy-5alpha-androst-2-eno(3,2-c)-pyrazole; Cyclopenta[7,8]phenanthro[2,3-c]pyrazole, 2'H-androst-2-eno[3,2-c]pyrazol-17-ol deriv.; (1S,2S,10S,13R,14S,17S,18S)-2,17,18-trimethyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5-dien-17-ol; 1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydro-1,10a,12a-trimethyl-Cyclopenta[7,8]phenanthro[2,3-c]pyrazol-1-ol; 17966-55-1; Cyclopenta[7,3-c]pyrazol-1-ol, 1,2,3,3a,3b,4,5,5a,6,8,10,10a,10b,11,12,12a-hexadecahydro-1,10a,12a-trimethyl-
• Indication:
  In total 1 Indication(s)
  Hereditary angioedema [ICD-11: 4A00]; Approved; [1]
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Validated by in-vivo Model for This Drug (1 diseases)
  Hereditary angioedema [ICD-11: 4B05]; [1]
• Target: .; NOUNIPROTAC; [1]
• Formula: C21H32N2O
• IsoSMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(CC5=C(C4)NN=C5)C
• InChI: 1S/C21H32N2O/c1-19-11-13-12-22-23-18(13)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)24/h12,14-17,24H,4-11H2,1-3H3,(H,22,23)/t14-,15+,16-,17-,19-,20-,21-/m0/s1
• InChIKey: LKAJKIOFIWVMDJ-IYRCEVNGSA-N
• PubChem CID: 25249
• ChEBI ID: CHEBI:9249
• TTD Drug ID: D08QKJ
• DrugBank ID: DB06718

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-04: Immune system diseases

Hereditary angioedema [ICD-11: 4B05]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Apoptosis regulator BAX (BAX) [1]

• Molecule Alteration: Expression; Up-regulation
• Resistant Disease: Hereditary angioedema [ICD-11: 4B05.0]
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vivo Model: Sprague Dawley male rats model; Rattus norvegicus
• Experiment for Molecule Alteration: Gene expression analysis
• Mechanism Description: Stanozolol can increases levels of Bax, Bcl-2, P53, caspase 3 and Bax/Bcl-2 ratio. Resistance training, 50 and 100 mg/kg Tribulus terrestris and resistance training along with Tribulus terrestris can decrease the Bax, Bcl-2, P53, caspase 3 and Bax/Bcl-2 ratio in rats exposed to Stanozolol.

Key Molecule: Apoptosis regulator Bcl-2 (BCL2) [1]

• Molecule Alteration: Expression; Up-regulation
• Resistant Disease: Hereditary angioedema [ICD-11: 4B05.0]
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vivo Model: Sprague Dawley male rats model; Rattus norvegicus
• Experiment for Molecule Alteration: Gene expression analysis
• Mechanism Description: Stanozolol can increases levels of Bax, Bcl-2, P53, caspase 3 and Bax/Bcl-2 ratio. Resistance training, 50 and 100 mg/kg Tribulus terrestris and resistance training along with Tribulus terrestris can decrease the Bax, Bcl-2, P53, caspase 3 and Bax/Bcl-2 ratio in rats exposed to Stanozolol.

Key Molecule: Caspase-3 (CASP3) [1]

• Molecule Alteration: Expression; Up-regulation
• Resistant Disease: Hereditary angioedema [ICD-11: 4B05.0]
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vivo Model: Sprague Dawley male rats model; Rattus norvegicus
• Experiment for Molecule Alteration: Gene expression analysis
• Mechanism Description: Stanozolol can increases levels of Bax, Bcl-2, P53, caspase 3 and Bax/Bcl-2 ratio. Resistance training, 50 and 100 mg/kg Tribulus terrestris and resistance training along with Tribulus terrestris can decrease the Bax, Bcl-2, P53, caspase 3 and Bax/Bcl-2 ratio in rats exposed to Stanozolol.

Key Molecule: Cellular tumor antigen p53 (TP53) [1]

• Molecule Alteration: Expression; Up-regulation
• Resistant Disease: Hereditary angioedema [ICD-11: 4B05.0]
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vivo Model: Sprague Dawley male rats model; Rattus norvegicus
• Experiment for Molecule Alteration: Gene expression analysis
• Mechanism Description: Stanozolol can increases levels of Bax, Bcl-2, P53, caspase 3 and Bax/Bcl-2 ratio. Resistance training, 50 and 100 mg/kg Tribulus terrestris and resistance training along with Tribulus terrestris can decrease the Bax, Bcl-2, P53, caspase 3 and Bax/Bcl-2 ratio in rats exposed to Stanozolol.

References

• Ref 1: Anti-Apoptotic Effects of Resistance Training and Tribulus Terrestris Consumption in the Heart Tissue of Rats Exposed to Stanozolol .Eurasian J Med. 2021 Jun;53(2):79-84. doi: 10.5152/eurasianjmed.2021.20051. 10.5152/eurasianjmed.2021.20051